Prof. Dr. med. Christoph Thomssen

Magnifier Icon Suche

kurze Vorstellung:

Herr Prof. Thomssen ist Ordinarius für Gynäkologie und Geburtshilfe an der Martin-Luther-Universität Halle-Wittenberg. Der Schwerpunkt seiner klinischen und wissenschaftlichen Arbeit liegt in der Gynäkologischen Onkologie und dem Mammakarzinom einschließlich der operativen und medikamentösen Therapie bei Primärdiagnose und in der Metastasierung. Er ist Leiter des zertifizierten Brustzentrums und zertifizierten Gynäkologischen Krebszentrums am Universitätsklinikum Halle (Saale).

Martin-Luther-Universität Halle-Wittenberg:

  1. Professor für Gynäkologie und Geburtshilfe
  2. Direktor der Universitätsklinik und Poliklinik für Gynäkologie
  • Leiter des Brustzentrums Universitätsklinkikum Halle
  • Leiter des Zentrums für Gynäkologische Krebserkrankungen Halle
  1. Ordentliches Mitglied des Klinischen Ethikkomitees am Universitätsklinikum Halle

Weitere Funktionen:

  1. Mitglied AGO Kommission Mamma (Leitlinien Mammakarzinom, Gründungsmitglied)
  2. Panelist of the International Consensus Conference for Advanced Breast Cancer (ABC)
  3. Mitglied Studiengruppe AGO Breast Study Group (AGO-B, Gründungsmitglied)
  4. Vertreter der Studiengruppe in der Breast International Group (B.I.G.)
  5. AGO Arbeitsgruppe „Global Cancer Care for Women“
  6. Mitglied im Deutschen Konsortium Familiärer Brust- und Eierstockkrebs (FBREK/HBOC)

Herausgeberschaften:

  1. Ko-Editor des wissenschaftlichen Journals „BREAST CARE“
  2. Mitherausgeber Coilloquium Senologie, Agileum

Klinische Studien:

  1. Studienleiter: NNBC-3 Europe
  2. Leiter klinische Prüfung Deutschland: APHINITY

Frühes und metastasiertes Mammakarzinom

                Diagnose, operative und medikamentöse Therapie, Prognosefaktoren

Gynäkologische Krebserkrankungen

                Diagnose, operative inkl. minimal-invasive operative sowie medikamentöse Therapie

Familiärer Brust- und Eierstockkrebs

Urogynäkologie

Prognosefaktoren und prädiktive Faktoren in der Behandlung des Mammakarzinoms

  • uPA, PAI-1
  • PAM 50
  • Subtypisierung tripelnegatives Mammakarzinom (Gene-Array-Analysen, Affymetrix U133)

Optimierung der operativen und medikamentösen Therapie des Mammakarzinoms

  • Prospektive klinische Studien inkl. IITs
    • NNBC 3-Europe (Rekrutierung abgeschlossen mit 4.149 Pat.; Studienleiter, IIT, Team Dr. Vetter, Dr. Kantelhardt, S Kaufhold)
    • APHINITY (LKP Deutschland, B.I.G./Roche, Team Dr. Steer, A. Füssel)
    • Destiny07 (LKP Deutschland, Daiichi Sankyo/Astra Zeneca; Team Dr. Steer, A. Füssel)
    • Prospektive Evaluation der VAB zur Bestimmung der Remission nach neoadjuvanter Therapie (Stanzstudie NACT, in house, Team Dr. Große, Dr. Zentgraf (Radiologie), K. Neumayer)
    • Prospektive Evaluation der Wiederauffindung prätherapeutisch markierter axillärer Lymphknoten im Rahmen der NACT (TAD, prospektive Beobachtungsstudie, in house; Team Dr. Steer)
    • Evaluation Ergebnisse platinhaltige neoadjuvante Therapie bei tripelnegativem frühen Mammakarzinom (eTNBC, prospektive Beobachtungsstudie, in house; Team Dr. Vetter, Dr. Reinhardt, L. van Uden, S. Kaufhold)
  • Prospektive wissenschaftliche und therapieoptimierende Studien in Kooperation mit nationalen und internationalen Studiengruppen:
    • Gynäkologische Tumoren: Studiengruppe AGO;
    • Mammakarzinom: AGO-B, WSG, GBG, GEICAM, Michelangelo (Team: A. Füssel (Study Nurse), Ärzteteam der Frauenklinik)

Übersicht der bestätigten und bewerteten Publikationen2019-2020


Prof. Dr. med. Christoph Thomssen


Journalbeitrag / Originalarbeiten

  1. Balic M, Thomssen C, Würstlein R, Gnant M, Harbeck N: (2019) St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment. BREAST CARE, 14: 103-110 31798382
    IF: 2,029, anteiliger IF: 0,22544
     
  2. Bauer M, Kantelhardt EJ, Stiewe T, Nist A, Mernberger M, Politt K, Hanf V, Lantzsch T, Uleer C, Peschel S, John J, Buchmann J, Weigert E, Bürrig KF, Wickenhauser C, Thomssen C, Bartel F, Vetter M: (2019) Specific Allelic Variants of SNPs in the MDM2 and MDMX genes are associated with earlier tumor onset and progression in Caucasian breast cancer patients. ONCOTARGET, 10: 1975-1992 30956778
    IF: 4,67, anteiliger IF: 0,09714
     
  3. Begoihn M, Mathewos A, Aynalem A, Wondemagegnehu T, Moelle U, Gizaw M, Wienke A, Thomssen C, Worku D, Addissie A, Jemal A, Kantelhardt EJ: (2019) Cervical cancer in Ethiopia - predictors of advanced stage and prolonged time to diagnosis. Infectious Agents and Cancer, 14: 36 31737087
    IF: 2,74, anteiliger IF: 0,09133
     
  4. Berchtold E, Vetter M, Gündert M, Csaba G, Fathke C, Ulbrich SE, Thomssen C, Zimmer R, Kantelhardt EJ: (2019) Comparison of six breast cancer classifiers using qPCR. BIOINFORMATICS, 35: 3412-3420 30759193
    IF: 5,61, anteiliger IF: 0,26714
     
  5. Ditsch N, Untch M, Thill M, Müller V, Janni W, Albert US, Bauerfeind I, Blohmer J, Budach W, Dall P, Diel I, Fasching PA, Fehm T, Friedrich M, Gerber B, Hanf V, Harbeck N, Huober J, Jackisch C, Kolberg-Liedtke C, Kreipe HH, Krug D, Kühn T, Kümmel S, Loibl S, Lüftner D, Lux MP, Maass N, Möbus V, Müller-Schimpfle M, Mundhenke C, Nitz U, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn HP, Solbach C, Solomayer EF, Stickeler E, Thomssen C, Wenz F, Witzel I, Wöckel A: (2019) AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019. BREAST CARE, 14: 224-245 31558897
    IF: 2,029, anteiliger IF: 0,01583
     
  6. Furlanetto J, von Minckwitz G, Lederer B, Möbus V, Schneeweiss A, Huober J, Fasching PA, Gerber B, Bauerfeind I, Nitz U, Lück HJ, Hanusch C, Thomssen C, Untch M, Nekljudova V, Mehta K, Loibl S: (2019) Fatal events during clinical trials: an evaluation of deaths during breast cancer studies. Breast Cancer, 26: 826-834 31254201
    IF: 2,695, anteiliger IF: 0,05983
     
  7. Huober J, Bartsch R, Marmé F, Pagani O, Thomssen C: (2019) Luminal Metastatic Breast Cancer. BREAST CARE, 14: 99-101 31798381
    IF: 2,029, anteiliger IF: 0,67633
     
  8. Kuhlmann JD, Bachmann HS, Link T, Wimberger P, Kröber E, Thomssen C, Mallé B, Bethmann D, Vetter M, Kantelhardt EJ: (2019) Association of caspase 8 polymorphisms -652 6N InsDel and Asp302His with progression-free survival and tumor infiltrating lymphocytes in early breast cancer. Scientific Reports, 9: 12594 31467295
    IF: 3,998, anteiliger IF: 0,16672
     
  9. Lüftner D, Bauerfeind I, Braun M, Brucker SY, Fasching PA, Felberbaum R, Hagemann F, Haidinger R, Harbeck N, Hönig A, Huober J, Jackisch C, Kolberg HC, Kolberg-Liedtke C, Kühn T, Maass N, Reimer T, Schneeweiss A, Schumacher-Wulf E, Schütz F, Thomssen C, Untch M, Wuerstlein R, Thill M: (2019) Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy - German Experts' Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019). BREAST CARE, 14: 315-324 31798392
    IF: 2,029, anteiliger IF: 0,03074
     
  10. Nabieva N, Häberle L, Brucker SY, Janni W, Volz B, Loehberg CR, Hartkopf AD, Walter CB, Baake G, Fridman A, Malter W, Wuerstlein R, Harbeck N, Hoffmann O, Kuemmel S, Martin B, Thomssen C, Graf H, Wolf C, Lux MP, Bayer CM, Rauh C, Hack CC, Almstedt K, Gass P, Heindl F, Brodkorb T, Lindner C, Kolberg HC, Krabisch P, Weigel M, Steinfeld-Birg D, Kohls A, Brucker C, Schulz V, Fischer G, Pelzer V, Rack B, Beckmann MW, Fehm T, Rody A, Maass N, Hein A, Fasching PA: (2019) Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients. INTERNATIONAL JOURNAL OF CANCER, 145: 2114-2121 30901076
    IF: 5,145, anteiliger IF: 0,04065
     
  11. Piszczan S, Desalegn D, Petros H, Gurmu M, Kroeber ES, Addissie A, Mikolajczyk R, Ghebre RG, Mathewos A, Thomssen C, Jemal A, Kantelhardt EJ: (2019) Clinical Characteristics and Survival of Patients with Malignant Ovarian Tumors in Addis Ababa, Ethiopia. ONCOLOGIST, 24: e303-e311 31023861
    IF: 5,025, anteiliger IF: 0,16733
     
  12. Thill M, Jackisch C, Janni W, Müller V, Albert US, Bauerfeind I, Blohmer J, Budach W, Dall P, Diel I, Fasching PA, Fehm T, Friedrich M, Gerber B, Hanf V, Harbeck N, Huober J, Kolberg-Liedtke C, Kreipe HH, Krug D, Kühn T, Kümmel S, Loibl S, Lüftner D, Lux MP, Maass N, Möbus V, Müller-Schimpfle M, Mundhenke C, Nitz U, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn HP, Solbach C, Solomayer EF, Stickeler E, Thomssen C, Untch M, Wenz F, Witzel I, Wöckel A, Ditsch N: (2019) AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019. BREAST CARE, 14: 247-255 31558898
    IF: 2,029, anteiliger IF: 0,01583
     
  13. Untch M, Thomssen C, Bauerfeind I, Braun M, Brucker SY, Felberbaum R, Hagemann F, Haidinger R, Hönig A, Huober J, Jackisch C, Kolberg HC, Kolberg-Liedtke C, Kühn T, Lüftner D, Maass N, Reimer T, Schneeweiss A, Schumacher-Wulf E, Schütz F, Thill M, Wuerstlein R, Fasching PA, Harbeck N: (2019) Primary Therapy of Early Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists on the 16th St. Gallen International Breast Cancer Conference (Vienna 2019). GEBURTSHILFE UND FRAUENHEILKUNDE, 79: 591-604 31217628
    IF: 2,382, anteiliger IF: 0,03621
     
  14. von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE, KATHERINE Investigators: (2019) Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. NEW ENGLAND JOURNAL OF MEDICINE, 380: 617-628 30516102
    IF: 74,699, anteiliger IF: 0,08217
     
  15. Wallwiener M, Nabieva N, Feisst M, Fehm T, de Waal J, Rezai M, Baier B, Baake G, Kolberg HC, Guggenberger M, Warm M, Harbeck N, Wuerstlein R, Deuker JU, Dall P, Richter B, Wachsmann G, Brucker C, Siebers JW, Popovic M, Kuhn T, Wolf C, Vollert HW, Breitbach GP, Janni W, Landthaler R, Kohls A, Rezek D, Noesselt T, Fischer G, Henschen S, Praetz T, Heyl V, Kühn T, Krauss T, Thomssen C, Hohn A, Tesch H, Mundhenke C, Hein A, Rauh C, Bayer CM, Schmidt K, Belleville E, Brucker SY, Hadji P, Beckmann MW, Wallwiener D, Kümmel S, Hartkopf A, Fasching PA: (2019) Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study. BMC CANCER, 19: 611 31227025
    IF: 3,15, anteiliger IF: 0,02142
     
  16. Wunderle M, Pretscher J, Brucker SY, Volz B, Hartmann A, Fiessler C, Hein A, Häberle L, Jud SM, Lux MP, Janni W, Loehberg CR, Hartkopf AD, Walter CB, Baake G, Fridman A, Malter W, Wuerstlein R, Harbeck N, Hoffmann O, Kümmel S, Martin B, Thomssen C, Graf H, Wolf C, Bayer CM, Hack CC, Almstedt K, Gass P, Heindl F, Brodkorb TF, Nabieva N, Lindner C, Kolberg HC, Krabisch P, Weigel M, Steinfeld-Birg D, Kohls A, Brucker C, Schulz V, Fischer G, Pelzer V, Wallwiener D, Rack B, Fehm T, Rody A, Maass N, Beckmann MW, Fasching PA, Rauh C: (2019) Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer. BREAST CANCER RESEARCH AND TREATMENT, 174: 453-461 30603996
    IF: 3,831, anteiliger IF: 0,0266
     

2019

Summe Bewertung = 2,02071

Summe IF = 124,09


Originalarbeiten

  1. Ditsch N, Untch M, Kolberg-Liedtke C, Jackisch C, Krug D, Friedrich M, Janni W, Müller V, Albert US, Banys-Paluchowski M, Bauerfeind I, Blohmer JU, Budach W, Dall P, Diel I, Fallenberg EM, Fasching PA, Fehm T, Gerber B, Gluz O, Hanf V, Harbeck N, Heil J, Huober J, Kreipe HH, Kühn T, Kümmel S, Loibl S, Lüftner D, Lux M, Maass N, Moebus V, Mundhenke C, Park-Simon TW, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Solbach C, Solomayer EF, Stickeler E, Thomssen C, Witzel I, Wöckel A, Thill M: (2020) AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2020. BREAST CARE, 15: 294-309 32774225
    IF: 2,029, anteiliger IF: 0,01542
     
  2. Hack CC, Häberle L, Brucker SY, Janni W, Volz B, Loehberg CR, Hartkopf AD, Walter CB, Baake G, Fridman A, Malter W, Wuerstlein R, Harbeck N, Hoffmann O, Kuemmel S, Martin B, Thomssen C, Graf H, Wolf C, Lux MP, Bayer CM, Rauh C, Almstedt K, Gass P, Heindl F, Brodkorb T, Willer L, Lindner C, Kolberg HC, Krabisch P, Weigel M, Steinfeld-Birg D, Kohls A, Brucker C, Schulz V, Fischer G, Pelzer V, Rack B, Beckmann MW, Fehm T, Rody A, Maass N, Hein A, Fasching PA, Nabieva N: (2020) Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients. BREAST, 50: 11-18 31958661
    IF: 3,754, anteiliger IF: 0,0291
     
  3. Ortmann O, Torode J, Schmiegel W, Thomssen C, Hakama M, Basu P, Ringborg U, Helbig U, participants of the ERTM: (2020) Knowledge transfer as a tool towards improvement of cancer care in low- and middle-income countries. 6th European Roundtable Meeting (ERTM), June 14th, 2019, Berlin, Germany. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 146: 1813-1818 32270287
    IF: 3,656, anteiliger IF: 0,17403
     
  4. Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J, KEYNOTE-522 Investigators: (2020) Pembrolizumab for Early Triple-Negative Breast Cancer. NEW ENGLAND JOURNAL OF MEDICINE, 382: 810-821 32101663
    IF: 74,699, anteiliger IF: 0,24651
     
  5. Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, Ciruelos E, Schneeweiss A, Loi S, Monturus E, Clark E, Knott A, Restuccia E, Benyunes MC, Cortés J, CLEOPATRA study group: (2020) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. LANCET ONCOLOGY, 21: 519-530 32171426
    IF: 33,752, anteiliger IF: 0,00675
     
  6. Thomssen C, Lüftner D, Untch M, Haidinger R, Würstlein R, Harbeck N, Augustin D, Briest S, Ettl J, Fasching PA, Förster F, Kurbacher CM, Lück HJ, Marschner N, Müller L, Müller V, Perlova-Griff L, Radke I, Ruckhäberle E, Scheffen I, Schumacher-Wulf E, Schwoerer M, Steinfeld-Birg D, Ziegler-Löhr K: (2020) International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus - Assessment by a German Group of Experts. BREAST CARE, 15: 82-95 32231503
    IF: 2,029, anteiliger IF: 0,67627
     
  7. Untch M, Würstlein R, Lüftner D, Haidinger R, Fasching PA, Augustin D, Briest S, Ettl J, Förster F, Kurbacher CM, Lück HJ, Marschner N, Müller L, Müller V, Radke I, Ruckhäberle E, Scheffen I, Schumacher-Wulf E, Schwoerer M, Steinfeld-Birg D, Ziegler-Löhr K, Thomssen C, Harbeck N: (2020) ABC5 International Consensus Conference on Advanced Breast Cancer, Lisbon, 16 November 2019: Commentary by the German panel of experts on the ABC5 voting results. GEBURTSHILFE UND FRAUENHEILKUNDE, 80: 588-600 32565549
    IF: 2,382, anteiliger IF: 0,03787
     

2020

Summe Bewertung = 1,18594

Summe IF = 122,301

 

Übersicht der bestätigten und bewerteten Publikationen 2017-2018


Prof. Dr. med. Christoph Thomssen


Journalbeitrag / Originalarbeiten

  1. Aapro M, De Laurentiis M, Rea D, Bargallo Rocha JE, Elizalde R, Landherr L, Linderholm B, Mamounas E, Markopoulos C, Neven P, Petrovsky A, Rouzier R, Smit V, Svedman C, Schneider D, Thomssen C, Martin M: (2017) The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2-) breast cancer: When might multigene assays be of value? BREAST, 33: 191-199 28441617
    IF: 2,951, anteiliger IF: 0,06558
     
  2. Bernhardt S, Bayerlová M, Vetter M, Wachter A, Mitra D, Hanf V, Lantzsch T, Uleer C, Peschel S, John J, Buchmann J, Weigert E, Bürrig KF, Thomssen C, Korf U, Beissbarth T, Wiemann S, Kantelhardt EJ: (2017) Proteomic profiling of breast cancer metabolism identifies SHMT2 and ASCT2 as prognostic factors. BREAST CANCER RESEARCH, 19: 112 29020998
    IF: 6,142, anteiliger IF: 0,12775
     
  3. Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E: (2017) Corrigendum to "3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)" [Breast 31 (February 2017) 244-259]. BREAST, 1: 1-10 28109648
    IF: 2,951, anteiliger IF: 0
     
  4. Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Pernault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E: (2017) 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). BREAST, 31: 244-259 27927580
    IF: 2,951, anteiliger IF: 0,02288
     
  5. Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Pernault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E: (2017) 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). ANNALS OF ONCOLOGY, 28: 16-33 28177437
    IF: 13,926, anteiliger IF: 0,10795
     
  6. Gnant M, Harbeck N, Thomssen C: (2017) St. Gallen/Vienna 2017: A Brief Summary of the Consensus Discussion about Escalation and De-Escalation of Primary Breast Cancer Treatment. BREAST CARE, 12: 102-107 28559767
    IF: 2,028, anteiliger IF: 0,676
     
  7. Hack CC, Fasching PA, Fehm T, de Waal J, Rezai M, Baier B, Baake G, Kolberg HC, Guggenberger M, Warm M, Harbeck N, Wuerstlein R, Deuker JU, Dall P, Richter B, Wachsmann G, Brucker C, Siebers JW, Fersis N, Kuhn T, Wolf C, Vollert HW, Breitbach GP, Janni W, Landthaler R, Kohls A, Rezek D, Noesslet T, Fischer G, Henschen S, Praetz T, Heyl V, Kühn T, Krauss T, Thomssen C, Hohn A, Tesch H, Mundhenke C, Hein A, Rauh C, Bayer CM, Jacob A, Schmidt K, Belleville E, Hadji P, Brucker SY, Wallwiener D, Kümmel S, Beckmann MW, Paepke D: (2017) Interest in Integrative Medicine Among Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study. INTEGRATIVE CANCER THERAPIES, 16: 165-175 27627986
    IF: 2,657, anteiliger IF: 0,01845
     
  8. Liedtke C, Thill M, Jackisch C, Thomssen C, Müller V, Janni W, Janni W, AGO Breast Committee*: (2017) AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2017. BREAST CARE, 12: 172-183 28785186
    IF: 2,028, anteiliger IF: 0,11267
     
  9. Möbus V, von Minckwitz G, Jackisch C, Lück HJ, Schneeweiss A, Tesch H, Elling D, Harbeck N, Conrad B, Fehm T, Huober J, Müller V, Bauerfeind I, du Bois A, Loibl S, Nekljudova V, Untch M, Thomssen C, German Breast Group (GBG) the AGO Breast Study Group (AGO-B) and NOGGO Study Groups: (2017) German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients. ANNALS OF ONCOLOGY, 28: 1803-1810 28459941
    IF: 13,926, anteiliger IF: 4,64154
     
  10. Nitz U, Gluz O, Huober J, Kreipe HH, Kates RE, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Möbus V, Augustin D, Hoffmann G, Weiss E, Böhmer S, Kreienberg R, Du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Kuhn W: (2017) Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression. ANNALS OF ONCOLOGY, 28: 2899 27634692
    IF: 13,926, anteiliger IF: 0,20183
     
  11. Thomssen C, El Saghir NS, Francis PA, Jassem J, Rugo HS, Untch M: (2017) Dual HER2 Blockade. BREAST CARE, 12: 345-349 29234257
    IF: 2,028, anteiliger IF: 0,676
     
  12. Trocchi P, Holzhausen HJ, Löning T, Böcker W, Schmidt-Pokrzywniak A, Thomssen C, Kluttig A, Stang A: (2017) Intraobserver Agreement on Histopathologic Evaluations of Core Breast Biopsies. Breast Journal, 23: 215-219 27868315
    IF: 2,424, anteiliger IF: 0,13467
     
  13. Untch M, Huober J, Jackisch C, Schneeweiss A, Brucker SY, Dall P, Denkert C, Fasching PA, Fehm T, Gerber B, Janni W, Kühn T, Lüftner D, Möbus V, Müller V, Rody A, Sinn P, Thill M, Thomssen C, Harbeck N, Liedtke C: (2017) Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017). GEBURTSHILFE UND FRAUENHEILKUNDE, 77: 633-644 28769126
    IF: 1,291, anteiliger IF: 0,02265
     
  14. van Rossum AGJ, Schouten PC, Weber KE, Nekljudova V, Denkert C, Solbach C, Köhne CH, Thomssen C, Forstbauer H, Hoffmann G, Kohls A, Schmatloch S, Schem C, von Minckwitz G, Karn T, Möbus VJ, Linn SC, Loibl S, Marmé F: (2017) BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial. BREAST CANCER RESEARCH AND TREATMENT, 166: 775-785 28822007
    IF: 3,605, anteiliger IF: 0,07069
     

2017

Summe Bewertung = 6,87864

Summe IF = 72,834


Originalarbeiten

  1. Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, Harbeck N, Aguilar Lopez B, Barrios CH, Bergh J, Biganzoli L, Boers-Doets CB, Cardoso MJ, Carey LA, Cortés J, Curigliano G, Diéras V, El Saghir NS, Eniu A, Fallowfield L, Francis PA, Gelmon K, Johnston SRD, Kaufman B, Koppikar S, Krop IE, Mayer M, Nakigudde G, Offersen BV, Ohno S, Pagani O, Paluch-Shimon S, Penault-Llorca F, Prat A, Rugo HS, Sledge GW, Spence D, Thomssen C, Vorobiof DA, Xu B, Norton L, Winer EP: (2018) 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†. ANNALS OF ONCOLOGY, 29: 1634-1657 30032243
    IF: 14,196, anteiliger IF: 0,1183
     
  2. Darlix A, Griguolo G, Thezenas S, Kantelhardt E, Thomssen C, Dieci MV, Miglietta F, Conte P, Braccini AL, Ferrero JM, Bailleux C, Jacot W, Guarneri V: (2018) Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer. JOURNAL OF NEURO-ONCOLOGY, 138: 369-382 29488184
    IF: 3,129, anteiliger IF: 0,09482
     
  3. Eber-Schulz P, Tariku W, Reibold C, Addissie A, Wickenhauser C, Fathke C, Hauptmann S, Jemal A, Thomssen C, Kantelhardt EJ: (2018) Survival of breast cancer patients in rural Ethiopia. BREAST CANCER RESEARCH AND TREATMENT, 170: 111-118 29479644
    IF: 3,471, anteiliger IF: 0,14474
     
  4. Gass P, Untch M, Müller V, Möbus V, Thomssen C, Häberle L, Erber R, Hein A, Jud SM, Lux MP, Hack CC, Hartmann A, Kolberg HC, Ettl J, Lüftner D, Jackisch C, Beckmann MW, Janni W, Schneeweiss A, Fasching PA, Nabieva N: (2018) Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients - a Survey Among Physicians. GEBURTSHILFE UND FRAUENHEILKUNDE, 78: 707-714 30057427
    IF: 1,312, anteiliger IF: 0,02302
     
  5. Griguolo G, Jacot W, Kantelhardt E, Dieci MV, Bourgier C, Thomssen C, Bailleux C, Miglietta F, Braccini AL, Conte P, Ferrero JM, Guarneri V, Darlix A: (2018) External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience. BREAST, 37: 36-41 29073498
    IF: 3,494, anteiliger IF: 0,10588
     
  6. Harbeck N, Lüftner D, Marschner N, Untch M, Augustin D, Briest S, Ettl J, Haidinger R, Müller L, Müller V, Ruckhäberle E, Wuerstlein R, Thomssen C: (2018) ABC4 Consensus: Assessment by a German Group of Experts. BREAST CARE, 13: 48-58 29950968
    IF: 2,087, anteiliger IF: 0,69567
     
  7. Hartkopf AD, Huober J, Volz B, Nabieva N, Taran FA, Schwitulla J, Overkamp F, Kolberg HC, Hadji P, Tesch H, Häberle L, Ettl J, Lux MP, Lüftner D, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wimberger P, Hielscher C, Geberth M, Fersis N, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Fasching PA, Janni W, Fehm TN, Wallwiener D, Brucker SY, Schneeweiss A: (2018) Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry. BREAST, 37: 42-51 29100043
    IF: 3,494, anteiliger IF: 0,03757
     
  8. Kroeber ES, Mathewos A, Wondemagegnehu T, Aynalem A, Gemechu T, Piszczan S, Timotewos G, Addissie A, Wienke A, Unverzagt S, Thomssen C, Jemal A, Kantelhardt EJ: (2018) Vulvar cancer in Ethiopia: A cohort study on the characteristics and survival of 86 patients. MEDICINE, 97: e0041 29489654
    IF: 1,87, anteiliger IF: 0,05667
     
  9. Möbus V, Jackisch C, Lueck HJ, du Bois A, Thomssen C, Kuhn W, Nitz U, Schneeweiss A, Huober J, Harbeck N, von Minckwitz G, Runnebaum IB, Hinke A, Konecny GE, Untch M, Kurbacher C, AGO Breast Study Group (AGO-B), Kahlert S, Hauser N, Marmé F, Kiesel L, Wallwiener D, Rautenberg B, Hofmann R, Barinoff J, Stickeler E, Eidtmann H, Müller V, Emons G, Mallmann P, Hackenberg R, Hielscher C, Räber G, Sommer H, Schmidt-Rhode P, Jahns B, von der Assen A, Dietterle S, Kaufmann M, Strunk C, Goebel R, Paepke S, Paulenz A, Junker-Stein A, Rhein U, Bremer K, Bauer W, Hohlweg-Majert P, Kramer D, Meerpohl HG, Diedrich K, Dall P, Kölbl H, Brückner B, Gros R, Stehle H, Lobodasch K, Dinkelacker T, Klöpper E, Karg C, Stibora M, Weise W, Melchert F, Mohrmann S, Klatt C, Schmidt M, Glados M, Mickan H, Pollmanns A, Beck T, Schröder W, Klingemann H, Köhler G, Freier W, Graßhoff ST, Söling U, Keil E, Höß C, Kullmer U, Niesel A, Bodenstein H, Bartzke G, Schlotter CM, Wiest W, Ernst W, Brudler O, Heinrich B, Hackmann J, Niedner W, Hoffmann G, Knapp W, Dresemann G, Karl C, Klemm FJ, Schliesser GC, Butterwegge M, Meden H, Kirschbaum M, Schwenzer T, Voigt HJ, Weiß U, Önder G, Langer W, Glaubitz M, Beha M, Coumbos A, Ko Y, Deuker JU, Prümmer O, Wagner U, Kohlstedt A, Schreiber P, Jovanovic V, Drzewiecki K, Guba H, Seipt H, Stauch M, Maintz C, Morenz B: (2018) Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial. ANNALS OF ONCOLOGY, 29: 178-185 29069370
    IF: 14,196, anteiliger IF: 0,04044
     
  10. Moelle U, Mathewos A, Aynalem A, Wondemagegnehu T, Yonas B, Begoihn M, Addissie A, Unverzagt S, Jemal A, Thomssen C, Vordermark D, Kantelhardt EJ: (2018) Cervical Cancer in Ethiopia: The Effect of Adherence to Radiotherapy on Survival. ONCOLOGIST, 23: 1024-1032 29567823
    IF: 5,252, anteiliger IF: 0,17489
     
  11. Nabieva N, Fehm T, Häberle L, de Waal J, Rezai M, Baier B, Baake G, Kolberg HC, Guggenberger M, Warm M, Harbeck N, Wuerstlein R, Deuker JU, Dall P, Richter B, Wachsmann G, Brucker C, Siebers JW, Popovic M, Kuhn T, Wolf C, Vollert HW, Breitbach GP, Janni W, Landthaler R, Kohls A, Rezek D, Noesselt T, Fischer G, Henschen S, Praetz T, Heyl V, Kühn T, Krauss T, Thomssen C, Hohn A, Tesch H, Mundhenke C, Hein A, Hack CC, Schmidt K, Belleville E, Brucker SY, Kümmel S, Beckmann MW, Wallwiener D, Hadji P, Fasching PA: (2018) Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study. EUROPEAN JOURNAL OF CANCER, 96: 82-90 29679775
    IF: 6,68, anteiliger IF: 0,04841
     
  12. Nabieva N, Kellner S, Fehm T, Häberle L, de Waal J, Rezai M, Baier B, Baake G, Kolberg HC, Guggenberger M, Warm M, Harbeck N, Wuerstlein R, Deuker JU, Dall P, Richter B, Wachsmann G, Brucker C, Siebers JW, Fersis N, Kuhn T, Wolf C, Vollert HW, Breitbach GP, Janni W, Landthaler R, Kohls A, Rezek D, Noesselt T, Fischer G, Henschen S, Praetz T, Heyl V, Kühn T, Krauss T, Thomssen C, Hohn A, Tesch H, Mundhenke C, Hein A, Rauh C, Bayer CM, Jacob A, Schmidt K, Belleville E, Brucker SY, Kümmel S, Beckmann MW, Wallwiener D, Hadji P, Fasching PA: (2018) Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients. ANNALS OF ONCOLOGY, 29: 186-192 29045642
    IF: 14,196, anteiliger IF: 0,09657
     
  13. Schmitt M, Wilhelm OG, Noske A, Schricker G, Napieralski R, Vetter M, Aubele M, Perkins J, Lauber J, Ulm K, Thomssen C, Martens JWM, Weichert W, Kiechle M: (2018) DNA Methylation to Predict Outcome in High-Risk Breast Cancer Patients Treated with Anthracycline-Based Chemotherapy. BREAST CARE, 13: 425-433 30800037
    IF: 2,087, anteiliger IF: 0,05797
     
  14. Untch M, Würstlein R, Marschner N, Lüftner D, Augustin D, Briest S, Ettl J, Haidinger R, Müller L, Müller V, Ruckhäberle E, Harbeck N, Thomssen C: (2018) 4th International Consensus Conference on Advanced Breast Cancer (ABC4), Lisbon, November 4, 2017 : ABC4 Consensus: Assessment by a Panel of German Experts. GEBURTSHILFE UND FRAUENHEILKUNDE, 78: 469-480 29880982
    IF: 1,312, anteiliger IF: 0,43733
     
  15. Weiner CM, Mathewos A, Addissie A, Ayele W, Aynalem A, Wondemagegnehu T, Wienke A, Jemal A, Zerche P, Thomssen C, Seidler A, Kantelhardt EJ: (2018) Characteristics and follow-up of metastatic breast cancer in Ethiopia: A cohort study of 573 women. BREAST, 42: 23-30 30149234
    IF: 3,494, anteiliger IF: 0,11635
     
  16. Wöckel A, Festl J, Stüber T, Brust K, Krockenberger M, Heuschmann PU, Jírů-Hillmann S, Albert US, Budach W, Follmann M, Janni W, Kopp I, Kreienberg R, Kühn T, Langer T, Nothacker M, Scharl A, Schreer I, Link H, Engel J, Fehm T, Weis J, Welt A, Steckelberg A, Feyer P, König K, Hahne A, Baumgartner T, Kreipe HH, Knoefel WT, Denkinger M, Brucker S, Lüftner D, Kubisch C, Gerlach C, Lebeau A, Siedentopf F, Petersen C, Bartsch HH, Schulz-Wendtland R, Hahn M, Hanf V, Müller-Schimpfle M, Henscher U, Roncarati R, Katalinic A, Heitmann C, Honegger C, Paradies K, Bjelic-Radisic V, Degenhardt F, Wenz F, Rick O, Hölzel D, Zaiss M, Kemper G, Budach V, Denkert C, Gerber B, Tesch H, Hirsmüller S, Sinn HP, Dunst J, Münstedt K, Bick U, Fallenberg E, Tholen R, Hung R, Baumann F, Beckmann MW, Blohmer J, Fasching P, Lux MP, Harbeck N, Hadji P, Hauner H, Heywang-Köbrunner S, Huober J, Hübner J, Jackisch C, Loibl S, Lück HJ, von Minckwitz G, Möbus V, Müller V, Nöthlings U, Schmidt M, Schmutzler R, Schneeweiss A, Schütz F, Stickeler E, Thomssen C, Untch M, Wesselmann S, Bücker A, Buck A, Stangl S: (2018) Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer. GEBURTSHILFE UND FRAUENHEILKUNDE, 78: 1056-1088 30581198
    IF: 1,312, anteiliger IF: 0,0046
     
  17. Wöckel A, Festl J, Stüber T, Brust K, Stangl S, Heuschmann PU, Albert US, Budach W, Follmann M, Janni W, Kopp I, Kreienberg R, Kühn T, Langer T, Nothacker M, Scharl A, Schreer I, Link H, Engel J, Fehm T, Weis J, Welt A, Steckelberg A, Feyer P, König K, Hahne A, Kreipe HH, Knoefel WT, Denkinger M, Brucker S, Lüftner D, Kubisch C, Gerlach C, Lebeau A, Siedentopf F, Petersen C, Bartsch HH, Schulz-Wendtland R, Hahn M, Hanf V, Müller-Schimpfle M, Henscher U, Roncarati R, Katalinic A, Heitmann C, Honegger C, Paradies K, Bjelic-Radisic V, Degenhardt F, Wenz F, Rick O, Hölzel D, Zaiss M, Kemper G, Budach V, Denkert C, Gerber B, Tesch H, Hirsmüller S, Sinn HP, Dunst J, Münstedt K, Bick U, Fallenberg E, Tholen R, Hung R, Baumann F, Beckmann MW, Blohmer J, Fasching PA, Lux MP, Harbeck N, Hadji P, Hauner H, Heywang-Köbrunner S, Huober J, Hübner J, Jackisch C, Loibl S, Lück HJ, von Minckwitz G, Möbus V, Müller V, Nöthlings U, Schmidt M, Schmutzler R, Schneeweiss A, Schütz F, Stickeler E, Thomssen C, Untch M, Wesselmann S, Bücker A, Krockenberger M: (2018) Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer. GEBURTSHILFE UND FRAUENHEILKUNDE, 78: 927-948 30369626
    IF: 1,312, anteiliger IF: 0,00472
     

2018

Summe Bewertung = 2,25795

Summe IF = 82,894

 

Übersicht der bestätigten und bewerteten Publikationen2015 - 2016


Prof. Dr. med. Christoph Thomssen


Journalbeitrag / Originalarbeiten

  1. Eggemann H, Ignatov T, Burger E, Kantelhardt EJ, Fettke F, Thomssen C, Costa SD, Ignatov A: (2015) Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer. ENDOCRINE-RELATED CANCER, 22: 725-33 26187126
    IF: 4,472, anteiliger IF: 0,24844
     
  2. Erber R, Gluz O, Brünner N, Kreipe HH, Pelz E, Kates R, Bartels A, Huober J, Mohrmann S, Moustafa Z, Liedtke C, Möbus V, Augustin D, Thomssen C, Jänicke F, Kiechle M, Kuhn W, Nitz U, Harbeck N, Hartmann A: (2015) Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial. BREAST CANCER RESEARCH AND TREATMENT, 150: 279-88 25721604
    IF: 4,085, anteiliger IF: 0,07565
     
  3. Gnant M, Thomssen C, Harbeck N: (2015) St. Gallen/Vienna 2015: A Brief Summary of the Consensus Discussion. BREAST CARE, 10: 124-30 26195941
    IF: 1,645, anteiliger IF: 0,54833
     
  4. Heil J, Kümmel S, Schaefgen B, Paepke S, Thomssen C, Rauch G, Ataseven B, Große R, Dreesmann V, Kühn T, Loibl S, Blohmer JU, von Minckwitz G: (2015) Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques. BRITISH JOURNAL OF CANCER, 113: 1565-70 26554654
    IF: 5,569, anteiliger IF: 0,16876
     
  5. Jackisch C, Harbeck N, Huober J, von Minckwitz G, Gerber B, Kreipe HH, Liedtke C, Marschner N, Möbus V, Scheithauer H, Schneeweiss A, Thomssen C, Loibl S, Beckmann MW, Blohmer JU, Costa SD, Decker T, Diel I, Fasching PA, Fehm T, Janni W, Lück HJ, Maass N, Scharl A, Untch M: (2015) 14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts. BREAST CARE, 10: 211-9 26557827
    IF: 1,645, anteiliger IF: 0,02384
     
  6. Loibl S, Schmidt A, Gentilini O, Kaufman B, Kuhl C, Denkert C, von Minckwitz G, Parokonnaya A, Stensheim H, Thomssen C, van Calsteren K, Poortmans P, Berveiller P, Markert UR, Amant F: (2015) Breast Cancer Diagnosed During Pregnancy: Adapting Recent Advances in Breast Cancer Care for Pregnant Patients. JAMA Oncology, 1: 1145-53 26247818
    IF: 0, anteiliger IF: 0
     
  7. Untch M, Harbeck N, Huober J, von Minckwitz G, Gerber B, Kreipe HH, Liedtke C, Marschner N, Möbus V, Scheithauer H, Schneeweiss A, Thomssen C, Jackisch C, Beckmann MW, Blohmer JU, Costa SD, Decker T, Diel I, Fasching PA, Fehm T, Janni W, Lück HJ, Maass N, Scharl A, Loibl S: (2015) Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015). GEBURTSHILFE UND FRAUENHEILKUNDE, 75: 556-565 26166836
    IF: 0,931, anteiliger IF: 0,01349
     
  8. von Minckwitz G, Conrad B, Reimer T, Decker T, Eidtmann H, Eiermann W, Hackmann J, Möbus V, Marmé F, Potenberg J, Stickeler E, Simon E, Thomssen C, Huober J, Denkert C, Alfer J, Jackisch C, Nekljudova V, Burchardi N, Loibl S, German Breast Group Investigators: (2015) A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52). CANCER, 121: 3639-48 26111104
    IF: 5,649, anteiliger IF: 0,09911
     

2015

Summe Bewertung = 1,17762

Summe IF = 23,996


Originalarbeiten

  1. Berndt U, Leplow B, Schoenfeld R, Lantzsch T, Grosse R, Thomssen C: (2016) Memory and Spatial Cognition in Breast Cancer Patients Undergoing Adjuvant Endocrine Therapy. BREAST CARE, 11: 240-246 27721710
    IF: 1,553, anteiliger IF: 0,51767
     
  2. Busch B, Bley N, Müller S, Glaß M, Misiak D, Lederer M, Vetter M, Strauß HG, Thomssen C, Hüttelmaier S: (2016) The oncogenic triangle of HMGA2, LIN28B and IGF2BP1 antagonizes tumor-suppressive actions of the let-7 family. NUCLEIC ACIDS RESEARCH, 44: 3845-64 26917013
    IF: 10,162, anteiliger IF: 0,42342
     
  3. Furlanetto J, Eiermann W, Marmé F, Reimer T, Reinisch M, Schmatloch S, Stickeler E, Thomssen C, Untch M, Denkert C, von Minckwitz G, Lederer B, Nekljudova V, Weber K, Loibl S, Möbus V: (2016) Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study. ANNALS OF ONCOLOGY, 27: 2053-2059 27502721
    IF: 11,855, anteiliger IF: 0,28226
     
  4. Gaß P, Fasching PA, Fehm T, de Waal J, Rezai M, Baier B, Baake G, Kolberg HC, Guggenberger M, Warm M, Harbeck N, Wuerstlein R, Deuker JU, Dall P, Richter B, Wachsmann G, Brucker C, Siebers JW, Fersis N, Kuhn T, Wolf C, Vollert HW, Breitbach GP, Janni W, Landthaler R, Kohls A, Rezek D, Noesselt T, Fischer G, Henschen S, Praetz T, Heyl V, Kühn T, Krauss T, Thomssen C, Hohn A, Tesch H, Mundhenke C, Hein A, Rauh C, Bayer CM, Jacob A, Schmidt K, Belleville E, Hadji P, Brucker SY, Beckmann MW, Wallwiener D, Kümmel S, Löhberg CR: (2016) Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study. BREAST CARE, 11: 315-322 27920623
    IF: 1,553, anteiliger IF: 0,01078
     
  5. Gluz O, Liedtke C, Huober J, Peyro-Saint-Paul H, Kates RE, Kreipe HH, Hartmann A, Pelz E, Erber R, Mohrmann S, Möbus V, Augustin D, Hoffmann G, Thomssen C, Jänicke F, Kiechle M, Wallwiener D, Kuhn W, Nitz U, Harbeck N, EC-Doc investigators (West German Study Group/AGO-B): (2016) Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial. ANNALS OF ONCOLOGY, 27: 1035-40 27022068
    IF: 11,855, anteiliger IF: 0,20798
     
  6. Schmidt M, Thomssen C, Untch M: (2016) Intrinsic Subtypes of Primary Breast Cancer - Gene Expression Analysis. Oncology Research and Treatment, 39: 102-10 27031354
    IF: 1,667, anteiliger IF: 0,55567
     
  7. Thomssen C, Augustin D, Ettl J, Haidinger R, Lück HJ, Lüftner D, Marmé F, Marschner N, Müller L, Overkamp F, Ruckhäberle E, Thill M, Untch M, Wuerstlein R, Harbeck N: (2016) ABC3 Consensus: Assessment by a German Group of Experts. BREAST CARE, 11: 61-70 27051399
    IF: 1,553, anteiliger IF: 0,51767
     
  8. Untch M, Augustin D, Ettl J, Haidinger R, Harbeck N, Lück HJ, Lüftner D, Marmé F, Müller L, Overkamp F, Ruckhäberle E, Thill M, Thomssen C, Wuerstlein R, Marschner N: (2016) ABC3 Consensus Commented from the Perspective of the German Guidelines: Third International Consensus Conference for Advanced Breast Cancer (ABC3), Lisbon, 07. 11. 2015. GEBURTSHILFE UND FRAUENHEILKUNDE, 76: 156-163 26941448
    IF: 1,07, anteiliger IF: 0,02744
     

2016

Summe Bewertung = 2,54288

Summe IF = 41,268

Übersicht der bestätigten und bewerteten Publikationen2013 bis 2014


Prof. Dr. med. Christoph Thomssen


JournalbeitragOriginalarbeiten

  1. Amant F, von Minckwitz G, Han SN, Bontenbal M, Ring AE, Giermek J, Wildiers H, Fehm T, Linn SC, Schlehe B, Neven P, Westenend PJ, Müller V, Van Calsteren K, Rack B, Nekljudova V, Harbeck N, Untch M, Witteveen PO, Schwedler K, Thomssen C, Van Calster B, Loibl S: (2013) Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. JOURNAL OF CLINICAL ONCOLOGY, 31: 2532-9 23610117
    IF: 17,96, anteiliger IF: 0,28514
     
  2. Harbeck N, Scharl A, Thomssen C, Müller V: (2013) AGO Recommendations for Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2013. BREAST CARE, 8: 181-5 24415967
    IF: 0,911, anteiliger IF: 0,15183
     
  3. Harbeck N, Thomssen C, Gnant M: (2013) St. Gallen 2013: brief preliminary summary of the consensus discussion. BREAST CARE, 8: 102-9 24000280
    IF: 0,911, anteiliger IF: 0,30367
     
  4. Lin NU, Thomssen C, Cardoso F, Cameron D, Cufer T, Fallowfield L, Francis PA, Kyriakides S, Pagani O, Senkus E, Costa A, Winer EP, European School of Oncology-Metastatic Breast Cancer Task Force: (2013) International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. BREAST, 22: 203-10 23601761
    IF: 2,581, anteiliger IF: 0,07823
     
  5. Lück HJ, Du Bois A, Loibl S, Schrader I, Huober J, Heilmann V, Beckmann M, Stähler A, Jackisch C, Hubalek M, Richter B, Stickeler E, Eidtmann H, Thomssen C, Untch M, Wollschläger K, Schuster T, von Minckwitz G: (2013) Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group. BREAST CANCER RESEARCH AND TREATMENT, 139: 779-87 23771714
    IF: 4,198, anteiliger IF: 0,08746
     
  6. Moebus V, Jackisch C, Schneeweiss A, Huober J, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Runnebaum IB, Hinke A, Kreienberg R, Untch M, AGO Breast Study Group: (2013) Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. JNCI-Journal of the National Cancer Institute, 105: 1018-26 23860204
    IF: 15,161, anteiliger IF: 0,38874
     
  7. Scharl A, Thomssen C, Harbeck N, Müller V: (2013) AGO Recommendations for Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2013. BREAST CARE, 8: 174-80 24415966
    IF: 0,911, anteiliger IF: 0,15183
     
  8. Thomssen C, Diel I, Gnant M, Goldmann-Posch U, Göschke C, Haidinger R, Janni W, Lin NU: (2013) Follow-up after breast cancer diagnosis. BREAST CARE, 8: 457-60 24550757
    IF: 0,911, anteiliger IF: 0,30367
     
  9. Thomssen C, Harbeck N: (2013) ABC2 Consensus Conference on Advanced Breast Cancer: Brief Summary of the Consensus Panel on Saturday November 9, 2013. BREAST CARE, 8: 455-6 24550756
    IF: 0,911, anteiliger IF: 0,4555
     
  10. Trocchi P, Holzhausen HJ, Böcker W, Schmidt-Pokrzywniak A, Ruschke K, Thomssen C, Löning T, Kluttig A, Stang A: (2013) Influence of immunohistochemistry on the final diagnosis of breast biopsies. HISTOPATHOLOGY, 63: 817-25 24236511
    IF: 3,301, anteiliger IF: 0,15719
     
  11. Untch M, Gerber B, Harbeck N, Jackisch C, Marschner N, Möbus V, von Minckwitz G, Loibl S, Beckmann MW, Blohmer JU, Costa SD, Decker T, Diel I, Dimpfl T, Eiermann W, Fehm T, Friese K, Jänicke F, Janni W, Jonat W, Kiechle M, Köhler U, Lück HJ, Maass N, Possinger K, Rody A, Scharl A, Schneeweiss A, Thomssen C, Wallwiener D, Welt A: (2013) 13th st. Gallen international breast cancer conference 2013: primary therapy of early breast cancer evidence, controversies, consensus - opinion of a german team of experts (zurich 2013). BREAST CARE, 8: 221-9 24415975
    IF: 0,911, anteiliger IF: 0,01047
     
  12. von Minckwitz G, Möbus V, Schneeweiss A, Huober J, Thomssen C, Untch M, Jackisch C, Diel IJ, Elling D, Conrad B, Kreienberg R, Müller V, Lück HJ, Bauerfeind I, Clemens M, Schmidt M, Noeding S, Forstbauer H, Barinoff J, Belau A, Nekljudova V, Harbeck N, Loibl S: (2013) German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. JOURNAL OF CLINICAL ONCOLOGY, 31: 3531-9 23980081
    IF: 17,96, anteiliger IF: 0,28508
     

2013

Summe Bewertung = 2,65881

Summe IF = 66,627


Originalarbeiten

  1. Harbeck N, Marschner N, Untch M, Decker T, Hegewisch-Becker S, Jackisch C, Huober J, Lück HJ, von Minckwitz G, Scharl A, Schneeweiss A, Tesch H, Welt A, Wuerstlein R, Thomssen C: (2014) Second International Consensus Conference on Advanced Breast Cancer (ABC2), Lisbon, 11/09/2013: The German Perspective. BREAST CARE, 9: 52-9 24803888
    IF: 0,627, anteiliger IF: 0,20898
     
  2. Kantelhardt EJ, Zerche P, Mathewos A, Trocchi P, Addissie A, Aynalem A, Wondemagegnehu T, Ersumo T, Reeler A, Yonas B, Tinsae M, Gemechu T, Jemal A, Thomssen C, Stang A, Bogale S: (2014) Breast cancer survival in Ethiopia: a cohort study of 1,070 women. INTERNATIONAL JOURNAL OF CANCER, 135: 702-9 24375396
    IF: 5,085, anteiliger IF: 0,12107
     
  3. Kantelhardt EJ, Mathewos A, Aynalem A, Wondemagegnehu T, Jemal A, Vetter M, Knauf E, Reeler A, Bogale S, Thomssen C, Stang A, Gemechu T, Trocchi P, Yonas B: (2014) The prevalence of estrogen receptor-negative breast cancer in Ethiopia. BMC CANCER, 14: 895 25433805
    IF: 3,362, anteiliger IF: 0,09346
     
  4. Kantelhardt EJ, Moelle U, Begoihn M, Addissie A, Trocchi P, Yonas B, Hezkiel P, Stang A, Thomssen C, Vordermark D, Gemechu T, Gebrehiwot Y, Wondemagegnehu T, Aynalem A, Mathewos A: (2014) Cervical cancer in Ethiopia: survival of 1,059 patients who received oncologic therapy. ONCOLOGIST, 19: 727-34 24951611
    IF: 4,865, anteiliger IF: 0,12454
     
  5. Schlitt A, Jordan K, Vordermark D, Schwamborn J, Langer T, Thomssen C: (2014) Cardiotoxicity and oncological treatments. Deutsches Arzteblatt International, 111: 161-8 24666651
    IF: 3,518, anteiliger IF: 1,17267
     

Comments and Letter

  1. Aapro MS, De Laurentiis M, Mamounas E, Martin M, Rea D, Rouzier R, Smit V, Thomssen C: (2014) 14p * adoption of multi-gene assays in hr +, her2- breast cancer (bc) patients in europe: results of the multidisciplinary application of genomics in clinical practice (magic) survey. ANNALS OF ONCOLOGY, 25 Suppl 1: i5-i6 24764428
    IF: 7,04, anteiliger IF: 0,23467
     
  2. Moebus V, Jackisch C, Schneeweiss A, Huober J, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz UA, Runnebaum IB, Hinke A, Kreienberg R, Untch M, AGO Breast Study Group: (2014) Response. JNCI-Journal of the National Cancer Institute, 106: djt452 24586093
    IF: 12,583, anteiliger IF: 0
     
  3. Thomssen C, Harbeck N: (2014) Cutting-edge therapy concepts - cure metastatic breast cancer? BREAST CARE, 9: 5-6 24803880
    IF: 0,627, anteiliger IF: 0,03135
     

2014

Summe Bewertung = 1,98674

Summe IF = 37,707